Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Nifty Pharma emerged as the sector of the day on Monday, gaining nearly 2.5% and marking its sharpest single-day rise in over two months. The rally was led by Sun Pharma, whose share price surged over 7%, recording its strongest single-day gain since July 2021, after announcing the proposed $11.75 billion Organon acquisition.
On Monday, the Nifty 50 index jumped 184 points to trade near the 24,083 level, with all key sectoral indices trading in the green. Among them, Nifty Pharma stood out as one of the strongest performers, gaining nearly 2.5% during the session.
This marked the sharpest single-day gain for the Nifty Pharma index in over two months. Most constituents of the index were trading higher, with Sun Pharma leading the rally.
Sun Pharma Records Sharpest Single-Day Gain Since July 2021
Sun Pharmaceutical share price gained over 7% on Monday, registering its sharpest single-day gain in nearly five years, since July 2021.
The rally came after the company announced that it had entered into a definitive agreement to acquire all outstanding shares of Organon for $14 per share in an all-cash transaction. The deal values Organon at an enterprise value of $11.75 billion.
Organon is a global healthcare company that was formed in 2021 through a spin-off from Merck, known as MSD outside the United States and Canada.
The company has built strong brand equity and trust among healthcare professionals, patients, regulators and other stakeholders. It is a global leader in women’s health, with a portfolio of more than 70 products across Women’s Health and General Medicines, including biosimilars.
Organon’s products are commercialised across 140 countries, with the US, Europe, China, Canada and Brazil among its largest markets. The company also has six manufacturing facilities across the European Union and emerging markets, supporting its global scale and supply network.
Together, Organon’s Women’s Health and General Medicines franchises reflect its focus on access, affordability and wider healthcare reach.
The proposed acquisition is aligned with Sun Pharma’s strategy of expanding its Innovative Medicines business. The combined entity is expected to become a stronger player in Established Brands and Branded Generics.
The deal will also help Sun Pharma enter the biosimilars segment as a top-10 global player. Organon’s product portfolio, global reach and strong stakeholder relationships are expected to complement Sun Pharma’s existing strengths and support long-term value creation.
If completed, Sun Pharma expects the combined company to become one of the top 25 global pharmaceutical companies, with combined revenue of $12.4 billion. The acquisition is also expected to make Sun Pharma a leading player in Established Brands and Branded Generics, while increasing the revenue share of Innovative Medicines to 27%.
The company also expects to become a top-three player in global Women’s Health, build a stronger commercial platform for future growth and emerge as the seventh-largest global biosimilar player. The combined business is expected to have a presence in 150 countries, including 18 large markets, each generating more than $100 million in revenue.
Sun Pharma also said the deal would strengthen cash generation, with EBITDA and cash flow expected to nearly double. This is expected to support deleveraging from a post-transaction Net Debt/EBITDA level of 2.3x.
Under the agreement, Sun Pharma will acquire 100% of Organon’s issued and outstanding shares for cash.
The acquisition will be funded through a combination of available cash resources and committed bank financing. The transaction will be carried out through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger.
The deal is expected to close in early 2027, subject to customary conditions, including regulatory approvals and approval from Organon shareholders.
With Monday’s strong move, the Nifty Pharma index has gained a little over 4% in April so far. On a year-to-date basis, the index is up 1.88%.
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading